Could crowd funding be a solution to the financing struggles of young biotech companies in the early stages of drug development? Clive Cookson talks to Andrew Ward about the benefits and pitfalls of this new model for financing medical science.

A transcript for this podcast is currently unavailable, view our accessibility guide.

Get alerts on News in Focus when a new story is published

Copyright The Financial Times Limited 2019. All rights reserved.
Reuse this content (opens in new window)

Comments have not been enabled for this podcast.

Follow the topics in this podcast